Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138476 | 0.78 | CYP3A4 (0.46) | ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL30702572 | 0.78 | TSHR (0.35) | TSHRCYP3A4POLBSMN1; SMN2 | |
| SCHEMBL1021682 | 0.78 | TSHR (0.35) | TSHRCYP3A4POLBSMN1; SMN2 | |
| SCHEMBL635149 | 0.78 | HDAC1 (0.37) | ALDH1A1TSHRACHEPOLBHTT | |
| SCHEMBL10318844 | 0.78 | ALDH1A1 (0.43) | ALDH1A1TSHRTDP1PRSS1PRSS2 | |
| SCHEMBL8587845 | 0.75 | ALDH1A1 (0.39) | ALDH1A1TSHRCYP3A4 | |
| SCHEMBL28996996 | 0.75 | ACHE (0.35) | ALDH1A1CYP3A4ACHE | |
| SCHEMBL2336556 | 0.74 | ALDH1A1 (0.40) | ALDH1A1TSHRTDP1PRSS1PRSS2 | |
| SCHEMBL6049118 | 0.73 | NOTUM (0.36) | — | |
| SCHEMBL28597745 | 0.70 | ALDH1A1 (0.52) | ALDH1A1TSHRTDP1PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119859156-A | Boron-nitrogen organic compound, preparation method and application thereof, composition and photoelectric device | 广东聚华印刷显示技术有限公司 | 2025-04-22 | — | — | CN | claimed |
| WO-2021012479-A1 | HYDROGENATED CYCLIC [8] AROMATIC HYDROCARBON COMPOUND AND PREPARATION METHOD THEREFOR | 清华大学 | 2021-01-28 | — | — | WO | claimed |
| WO-2021012478-A1 | HYDROGENATION ANNULE [12] AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR | 清华大学 | 2021-01-28 | — | — | WO | claimed |
| CN-110372468-B | Hydrogenated endless [8] arene compound and preparation method thereof | 清华大学 | 2020-11-10 | — | — | CN | claimed |
| CN-110372469-B | Hydrogenated cyclo [12] arene compound and preparation method thereof | 清华大学 | 2020-09-08 | — | — | CN | claimed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| CN-119859156-A | Boron-nitrogen organic compound, preparation method and application thereof, composition and photoelectric device | 广东聚华印刷显示技术有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119080771-A | N-heterocyclic carbene compounds and application thereof | 中国科学院上海有机化学研究所 | 2024-12-06 | — | — | CN | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-117105892-A | Synthesis method of 3,4,3 ', 4' -p-terphenyl tetracarboxylic dianhydride | 大连新阳光材料科技有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116547272-A | Process for producing ketone derivative | 株式会社德山 | 2023-08-04 | — | — | CN | disclosed |
| EP-0008164-B1 | PHOSPHINITES AND PHOSPHONITES, THEIR PREPARATION AND USE AS ACRYLONITRILE DIMERISATION CATALYSTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-04-20 | — | — | EP | disclosed |
| US-4238422-A | CATALYSTS FOR DIMERIZATION OF ACRYLONITRILE | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-12-09 | — | — | US | disclosed |
| EP-0008164-A1 | Phosphinites and phosphonites, their preparation and use as acrylonitrile dimerisation catalysts | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-02-20 | — | — | EP | disclosed |
| US-4188396-A | ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1980-02-12 | — | — | US | disclosed |
| US-3965180-A | CNS DEPRESSANT | THE UPJOHN COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | ALDH1A1 2743/4885TSHR 475/4885TDP1 4598/4885 |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | ALDH1A1 2574/4885TSHR 1000/4885TDP1 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.